UBS upgraded Fresenius Medical to Neutral from Sell with a price target of EUR 40.5, down from EUR 42. A deep dive on the chronic kidney disease funnel and assessment of the potential for next-generation GLP-1s to slow CKD progression shows lower long-term growth ahead, but this is already largely priced-in, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on FMS:
- BJ’s Wholesale names Anjana Harve as chief information officer
- Fresenius Medical price target raised to EUR 40.50 at Morgan Stanley
- Fresenius Medical downgraded to Neutral from Buy at UBS
- Fresenius Medical price target raised to EUR 46 from EUR 38 at Deutsche Bank
- Fresenius Medical price target raised to EUR 45 from EUR 42 at Credit Suisse